Filing Details
- Accession Number:
- 0000315066-15-002590
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-05-07 16:49:56
- Reporting Period:
- 2015-05-05
- Filing Date:
- 2015-05-07
- Accepted Time:
- 2015-05-07 16:49:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1597264 | Blueprint Medicines Corp | BPMC | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 315066 | Fmr Llc | 245 Summer Street Boston MA 02210 | No | No | Yes | Yes |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-05-05 | 1,818,181 | $0.00 | 1,818,181 | No | 4 | C | Indirect | Beacon Bioventures Fund III Limited Partnership |
| Common Stock | Acquisiton | 2015-05-05 | 469,696 | $0.00 | 2,287,877 | No | 4 | C | Indirect | Beacon Bioventures Fund III Limited Partnership |
| Common Stock | Acquisiton | 2015-05-05 | 87,834 | $0.00 | 2,375,711 | No | 4 | C | Indirect | Beacon Bioventures Fund III Limited Partnership |
| Common Stock | Acquisiton | 2015-05-05 | 125,000 | $18.00 | 2,500,711 | No | 4 | P | Indirect | Beacon Bioventures Fund III Limited Partnership |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | Beacon Bioventures Fund III Limited Partnership |
| No | 4 | C | Indirect | Beacon Bioventures Fund III Limited Partnership |
| No | 4 | C | Indirect | Beacon Bioventures Fund III Limited Partnership |
| No | 4 | P | Indirect | Beacon Bioventures Fund III Limited Partnership |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Convertible Preferred Stock | Acquisiton | 2015-05-05 | 10,000,000 | $0.00 | 1,818,181 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Acquisiton | 2015-05-05 | 2,583,333 | $0.00 | 469,696 | $0.00 |
| Common Stock | Series C Convertible Preferred Stock | Acquisiton | 2015-05-05 | 483,092 | $0.00 | 87,834 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- On May 5, 2015, in connection with the completion of the issuer's initial public offering, all shares of Convertible Preferred Stock converted into Common Stock on a 5.5-for-1 basis.
- FMR Co., Inc. and Pyramis Global Advisors, LLC, each an indirect wholly-owned subsidiary of FMR LLC and an investment adviser registered under the Investment Advisers Act of 1940, and Pyramis Global Advisors Trust Company, an indirect wholly-owned subsidiary of FMR LLC and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934, are the beneficial owners of Common Stock of Blueprint Medicines Corp., as a result of acting as investment adviser to various investment companies registered under the Investment Company Act of 1940, institutional accounts and non-U.S. mutual funds. FMR LLC, Edward C. Johnson 3d and Abigail P. Johnson have no pecuniary interest in the Common Stock beneficially owned by FMR Co., Inc. and Pyramis Global Advisors, LLC and Pyramis Global Advisors Trust Company and Column 5 of Table I does not include such shares.
Billionaire Hedge Funds
